ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 39420366

Stable triangle: nanomedicine-based synergistic application of phototherapy and immunotherapy for tumor treatment.

Cai W and 7 others. J Nanobiotechnology, 2024. Cited by 21 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Stable triangle: nanomedicine-based synergistic application of phototherapy and immunotherapy for tumor treatment. Papers, record 39420366. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39420366

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Stable triangle: nanomedicine-based synergistic application of phototherapy and immunotherapy for tumor treatment.
PubMed
Journal
J Nanobiotechnology
PubMed
Year
2024
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
21
iCite
Relative citation ratio, by iCite
3.4, provisional
iCite
Revised in PubMed
2024-10-20
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Cai WWenjing
2Sun TTuyue
3Qiu CChenyu
4Sheng HHuixiang
5Chen RRuijie
6Xie CCongying
7Kou LLongfa
8Yao QQing

Source PubMed

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
ImmunotherapyMajor topic
NeoplasmsMajor topic
NanomedicineMajor topic
PhototherapyMajor topic
Humans
Combined Modality Therapy
Animals
Drug Delivery Systems
Nanoparticle Drug Delivery System

Source PubMed

Grants4

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
Y20210212Wenzhou Municipal Science and Technology BureauPubMed
LYY22H300001Natural Science Foundation of Zhejiang ProvincePubMed
Health innovation talents programHealth Commission of Zhejiang ProvincePubMed
YS2022-2-001Zhejiang Medical Doctor AssociationPubMed

Source PubMed

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References189

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
130,721,651Advances in the techniques and methodologies of cancer gene therapy.Discov Med2019https://conductscience.org/library/papers/30721651PubMed
213,130,303Targeting HIF-1 for cancer therapy.Nat Rev Cancer2003https://conductscience.org/library/papers/13130303PubMed
331,767,446Modulation of tumor microenvironment using a TLR-7/8 agonist-loaded nanoparticle system that exerts low-temperature hyperthermia and immunotherapy for in situ cancer vaccination.Biomaterials2020https://conductscience.org/library/papers/31767446PubMed
421,888,934Photoactivation switch from type II to type I reactions by electron-rich micelles for improved photodynamic therapy of cancer cells under hypoxia.J Control Release2011https://conductscience.org/library/papers/21888934PubMed
533,019,627Transporter-Targeted Nano-Sized Vehicles for Enhanced and Site-Specific Drug Delivery.Cancers (Basel)2020https://conductscience.org/library/papers/33019627PubMed
621,995,569NK cells: immune cross-talk and therapeutic implications.Immunotherapy2011https://conductscience.org/library/papers/21995569PubMed
736,386,474Cascade two-stage tumor re-oxygenation and immune re-sensitization mediated by self-assembled albumin-sorafenib nanoparticles for enhanced photodynamic immunotherapy.Acta Pharm Sin B2022https://conductscience.org/library/papers/36386474PubMed
835,493,513Impact of Manufacturing Procedures on CAR T Cell Functionality.Front Immunol2022https://conductscience.org/library/papers/35493513PubMed
924,224,474Carbon nanotube scaffolds instruct human dendritic cells: modulating immune responses by contacts at the nanoscale.Nano Lett2013https://conductscience.org/library/papers/24224474PubMed
1023,292,347Antimalarial pharmacology and therapeutics of atovaquone.J Antimicrob Chemother2013https://conductscience.org/library/papers/23292347PubMed

1 to 10 of 189

See all 189 references

Cited by12

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 21 citations.

PMIDTitleJournalYearIn PapersSource
42,761,669Precision Multimodal Nanodynamic Therapy for Lung Cancer: From Tumor Microenvironment-Responsive Platforms to Cell-Death Reprogramming and Immune Remodeling.Int J Nanomedicine2026https://conductscience.org/library/papers/42761669PubMed
42,559,258Ligand-modified multifunctional liposome-based targeted delivery platform: a multimodal cancer combination therapy strategy.Theranostics2026https://conductscience.org/library/papers/42559258PubMed
42,434,841Carrier-Free Nanoparticles Enhance Photothermal-Immune Therapy via Metabolic Reprogramming in Triple-Negative Breast Cancer.Adv Healthc Mater2026https://conductscience.org/library/papers/42434841PubMed
42,367,296Intelligent CpG nanoplatforms for targeted cancer immunotherapy and immune remodeling.Front Pharmacol2026https://conductscience.org/library/papers/42367296PubMed
42,340,392Bioengineered bacteria in cancer immunotherapy: mechanistic advances, therapeutic strategies and clinical potential.Arch Microbiol2026https://conductscience.org/library/papers/42340392PubMed
42,164,815Recent Advances in Nanomedicine for Targeted Phototherapy in Head and Neck Cancer.Int J Nanomedicine2026https://conductscience.org/library/papers/42164815PubMed
41,928,199IL-15 promotes immune escape, invasion, and metastasis of pancreatic cancer by upregulating PD-L1 expression via the JAK1/STAT1/IRF1 pathway.Cell Commun Signal2026https://conductscience.org/library/papers/41928199PubMed
41,839,827Nanoparticles-based phototherapy systems: molecular mechanisms and clinical applications.Signal Transduct Target Ther2026https://conductscience.org/library/papers/41839827PubMed
41,815,862PMPCylated liposomes in drug delivery and beyond.Mater Today Bio2026https://conductscience.org/library/papers/41815862PubMed
41,743,232Nanotechnology-Driven Precision Modulation of Transplant Immunity: From Mechanistic Insights to Clinical Tolerance.Int J Nanomedicine2026https://conductscience.org/library/papers/41743232PubMed

1 to 10 of 12

See all 12 cited by

Genes0

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

None in this release.

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39420366

GET https://conductscience.org/api/papers/v1/39420366/references?page=2

API referenceFor AI assistants